Irisin-related cancer treatments
In one embodiment, the invention provides methods of treating or preventing cancer, in particular aspects breast and/or prostate cancer, by administering to a subject in need thereof a therapeutically-effective amount of irisin and, optionally, one or more adjuvant therapies (e.g. synergistic co-administration of an additional anti-cancer agent or chemotherapy). Related pharmaceutical compositions, assays and kits are also provided.
1. A method of treating a subject who suffers from prostate or breast cancer, the method comprising administering to the subject a composition comprising a therapeutically effective amount of irisin, wherein said irisin is a polypeptide consisting of the sequence SEQ ID NO: 1, or the sequence SEQ ID NO: 2, or a glycosylated form of said polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein said irisin is a polypeptide consisting of SEQ ID NO:1 , or a pharmaceutically acceptable salt thereof.
3. The method according to claim 1 wherein said irisin is a polypeptide consisting of SEQ ID NO: 2, or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 wherein said cancer is breast cancer.
5. The method according to claim 1 wherein said cancer is refractory breast cancer.
6. The method according to claim 1 wherein said cancer is recurrent breast cancer.
7. The method according to claim 1 wherein said breast cancer is drug resistant breast cancer.
8. The method according to claim 1 wherein said breast cancer is metastatic breast cancer.
9. The method according to claim 1 wherein said breast cancer has developed an acquired anti-estrogen resistance.
10. The method according to claim 1 wherein said breast cancer has developed an acquired anti-estrogen resistance.
11. The method according to claim 1 wherein said cancer is breast cancer and the subject exhibits an intrinsic resistance to anti-estrogen and anti-HER2 therapies.
12. The method according to claim 1 wherein said composition further includes doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof.
13. The method according to claim 2 wherein said composition further includes doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof.
14. The method according to claim 3 wherein said composition further includes doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof.
15. The method according to claim 4 wherein said composition further includes doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof.
16. The method according to claim 5 wherein said composition further includes doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof.
17. The method according to claim 1 wherein said method comprises co-administering doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof to said subject.
18. The method according to claim 2 wherein said method comprises co-administering doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof to said subject.
19. The method according to claim 3 wherein said method comprises co-administering doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof to said subject.
20. The method according to claim 4 wherein said method comprises co-administering doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof to said subject.
21. The method according to claim 5 wherein said method comprises co-administering doxorubicin, daunorubicin or a pharmaceutically acceptable salt thereof to said subject.
22. The method according to claim 1 wherein said composition further includes doxorubicin or a pharmaceutically acceptable salt thereof.
23. The method according to claim 2 wherein said composition further includes doxorubicin or a pharmaceutically acceptable salt thereof.
24. The method according to claim 3 wherein said composition further includes doxorubicin or a pharmaceutically acceptable salt thereof.
25. The method according to claim 4 wherein said composition further includes doxorubicin or a pharmaceutically acceptable salt thereof.
26. The method according to claim 5 wherein said composition further includes doxorubicin or a pharmaceutically acceptable salt thereof.
27. The method according to claim 1 wherein said method comprises co-administering doxorubicin or a pharmaceutically acceptable salt thereof to said subject.
28. The method according to claim 2 wherein said method comprises co-administering doxorubicin or a pharmaceutically acceptable salt thereof to said subject.
29. The method according to claim 3 wherein said method comprises co-administering doxorubicin or a pharmaceutically acceptable salt thereof to said subject.
30. The method according to claim 4 wherein said method comprises co-administering doxorubicin or a pharmaceutically acceptable salt thereof to said subject.
31. The method according to claim 5 wherein said method comprises co-administering doxorubicin or a pharmaceutically acceptable salt thereof to said subject.